Liferol (Formoterol Fumarate)

Formoterol fumarate selectively binds to β2‑adrenergic receptors on airway smooth‑muscle cells, activating adenylate cyclase and raising cyclic AMP levels. The increase in cAMP causes relaxation of the smooth muscle, leading to prolonged bronchodilation that improves airflow for up to 12 hours after inhalation.

The dose of Liferol is individualized by the prescribing healthcare professional based on the patient’s disease severity, age, and response to therapy. The prescriber determines the number of inhalations per day and the specific inhaler device to be used.

Safety data for formoterol fumarate in pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made in consultation with a qualified healthcare provider.

To order Liferol, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Liferol (formoterol) is a long‑acting β2‑agonist that provides sustained bronchodilation for up to 12 hours, whereas short‑acting agents such as albuterol act for a few hours. Compared with other LABAs like salmeterol, formoterol has a faster onset of action while maintaining a similar duration, making it suitable for both maintenance and rescue use under medical guidance.

Liferol should be stored at ambient temperature, below 25 °C, in its original packaging. Keep the inhaler away from moisture, direct sunlight, and heat sources to preserve drug potency and device functionality.

Liferol is delivered via an inhalation device. The patient inhales the prescribed number of puffs through the mouthpiece, ensuring a slow, deep breath to allow the medication to reach the lower airways. Proper technique should be demonstrated by a healthcare professional before regular use.

Serious risks include paradoxical bronchospasm, which can worsen breathing, and cardiovascular effects such as tachycardia, arrhythmias, or angina. Patients should seek immediate medical attention if they experience sudden shortness of breath, chest pain, rapid heartbeat, or signs of an allergic reaction.

Liferol is contraindicated in patients with known hypersensitivity to formoterol fumarate or any component of the inhaler. It should also be avoided in individuals with severe cardiovascular disorders, uncontrolled hypertension, or those taking non‑selective β‑blockers unless directed by a physician.